Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of personalized medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Dec 28, 2021

Bill Hinshaw is the President and CEO of Axcella Therapeutics, a clinical-stage biotech company founded by Flagship Pioneering, Founder of Moderna. Using their platform to create compositions of endogenous metabolic modulators, EMMs, Axcella has generated two liver programs including 1125 for treating NASH.  Preclinical and clinical data led them to test 1125 for long COVID fatigue in conjunction with Dr. Betty Raman Senior Clinical Research Fellow in the Radcliffe Department of Medicine at the University of Oxford.

Bill explains, "So 1125 is a composition of amino acids and their derivatives, which is put together to address specific biologies. And we have tested it all the way into phase 2b in NASH patients. And what we've seen is it has an effect on important energy aspects, so bioenergetics, along with inflammatory redox, and immune and muscle functions."

"And what happens, in this case, is that basically, the virus comes in, hijacks the mitochondria to help it reproduce or redirect its efforts towards producing more virus. And when it does that, it damages the cell itself and its ability to create energy."

"Dr. Raman likes to talk about the fact that there's a battery, think of it as a rechargeable battery but unfortunately, in this case, the battery is damaged and it can't hold its charge. And so what 1125 is looking to do is to repair the battery's processes through areas like fatty acid oxidation, ATP generation, immune enhancement, as well as inflammatory reduction."

#Axcella #AxcellaLongCovid #AxcellaTherapeutics #OxfordLongCOVID #LongCOVID #COVID19 #COVID #ChronicFatigueLongCOVID #LongHaulers #ClinicalTrials

AxcellaTx.com

Listen to the podcast here

Axcella